BioSpace News Archive

Gamma Biosciences , a global life sciences company serving the advanced therapy market, today announced two additions to the senior management team of Astrea Bioseparations. Gabe Longoria will join Astrea as Chief Commercial Officer effective April 5 .

Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), today announced that its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), a psychedelics biotech company, has entered into a sponsored research agreement with The Queen’s University of Belfast

Cardiovascular Systems, Inc. to Participate at the 20 th Annual Needham Healthcare Conference

Bruker Corporation (Nasdaq: BRKR), a leading supplier of single-plane illumination microscopy (SPIM) technology for research on live cells and cleared biological samples, today announced that two Luxendo MuVi™ and LCS SPIM™ light-sheet microscopes have been installed by Memorial Sloan Kettering Cancer Center (MSK).

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors.

Second Sight Medical Products, Inc. (NASDAQ: EYES), (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into definitive securities purchase agreements with accredited investors for a private placement that will result in gross proceeds to Second Sight

DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexarias Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna, will present new nonclinical data discussing the Company’s GalXC-Plus™ RNAi technology as part of the sixth annual Oligonucleotide and Precision Therapeutics (OPT)

BioPrep Solutions (BioPrep) was founded, on the belief that public health should be public, meaning that the general public should have access to public health experts, that will provide the facts and make the plans that lead to active response and recovery to public health threats, like COVID-19.